Article

Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial

2023-07-13

Abstract excerpt

<h4>IMPORTANCE</h4> Treatment options for coronavirus disease 2019 (COVID-19) that can be used irrespective of risk factors for severe disease are warranted. <h4>OBJECTIVE</h4> To assess the efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19. <h4>DESIGN</h4> The phase 3 part of a phase 2/3, double-blind, randomized, placebo-controlled study conducted from February 10 to July 10, 2022. <h...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 06965b6e-9f6d-5ac1-a3fd-237f732631bc
DOI: 10.1101/2023.07.11.23292264

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical TrialDOI 10.1101/2023.07.11.23292264Read

A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)Semantic proximity Read

Effectiveness of Molnupiravir for the Treatment of COVID-19: A Systematic Literature Review of Real-World Observational StudiesSemantic proximity Read

Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in ScotlandSemantic proximity Read

Molnupiravir, an Oral Antiviral Treatment for COVID-19Semantic proximity Read

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and MexicoSemantic proximity Read

Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platformSemantic proximity Read

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-label Clinical TrialSemantic proximity Read

Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in EnglandSemantic proximity Read

Effectiveness of Community-Based Oral Antiviral Treatments Against Severe COVID-19 Outcomes in Victoria, Australia, 2022: An Observational StudySemantic proximity Read

A snapshot of the ongoing clinical research on COVID-19Semantic proximity Read

Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant SurgeSemantic proximity Read